Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.

Mohamad E AllafSe-Eun KimViraj MasterDavid F McDermottLauren C HarshmanSuzanne M ColeCharles G DrakeSabina SignorettiMahmut AkgulNicholas BaniakElsa Li-NingMatthew B PalmerHamid EmamekhooNabil AdraHristos KaimakliotisYasser GedPhillip M PierorazioE Jason AbelMehmet A BilenKenneth OganHelen H MoonKrishna A RamaswamyEric A SingerTina M MayerJay LohreyVitaly MargulisJessie GillsScott E DelacroixMark J WaplesAndrew C JamesPeng WangToni ChoueiriM Dror MichaelsonAnil KapoorDaniel Y HengBrian ShuchBradley C LeibovichPrimo N LaraJudith ManolaDeborah MaskensDena BattleRobert UzzoGennady BratslavskyNaomi B HaasMichael A Carducci

Published in: The Lancet. Oncology (2024)

US National Institutes of Health National Cancer Institute and Bristol Myers Squibb.

Keyphrases

renal cell carcinoma
open label
double blind
placebo controlled
clinical trial
public health
healthcare
robot assisted
cardiac surgery
quality improvement
patients undergoing
mental health
study protocol
health information
health promotion
editorial comment
randomized controlled trial
human health